ECE1

Across TCGA pan-cancer cohorts, ECE1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECE1 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ECE1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECE1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, STAD, and PRAD are the cancer types where ECE1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.279	0.542	.036	12	view →
STAD	OS	Median	All	0.259	0.734	.003	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.923	0.662	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECE1–OV (DFS)

Open the OV breakdown →